EKG
Polymorphic Ventricular Tachycardia
search
Polymorphic Ventricular Tachycardia
, Polymorphic VT, Torsades de Pointes, Torsades
See Also
Monomorphic Ventricular Tachycardia
Ventricular Tachycardia Management in the Adult
Ventricular Tachycardia Management in the Child
Unstable Tachycardia
Cardiac Arrest
Pathophysiology
Wide complex
Ventricular Tachycardia
Polymorphic VT Is higher risk than
Monomorphic VT
for degeneration into
Ventricular Fibrillation
Polymorphic Ventricular Tachycardia (VT) has a continuously changing QRS morphology
Unstable ventricular activation from multiple shifting foci or reentrant rhythm
Contrast with
Monomorphic VT
triggered from a single ventricular focus with uniform QRS
Polymorphic VT is divided into 2 main types
Polymorphic VT with
Prolonged QT
c (Torsades de Pointes)
Polymorphic VT with Normal QTc (most commonly
Myocardial Infarction
)
Causes
Polymorphic VT with
Prolonged QT
c (Torsades de Pointes)
See
QT Prolongation
Polymorphic VT with Normal QTc
Acute
Myocardial Infarction
(most common cause)
Myocardial Ischemia
alters myocardial ion gradients,
Action Potential
durations and refractory period
Results in conduction velocity differences across different myocardial regions
Triggers chaotic and irregular ventricular depolarization, and prevents regular reentry circuit of
Monomorphic VT
Concurrent factors contributing to Polymorphic VT risk
Sympathetic activation
Structural heart disease (e.g.
Brugada Syndrome
)
Management
See
Ventricular Tachycardia Management in the Adult
See
Ventricular Tachycardia Management in the Child
See
Unstable Tachycardia
INITIAL Steps
ABC Management
(and IV-O2-monitor)
See
Cardiac Arrest
Differentiation based on
QT Interval
is directed at prevention of recurrent
Arrhythmia
Immediate
Synchronized Cardioversion
Immediate
Defibrillation
(non-
Synchronized Cardioversion
) if
Defibrillator
is unable to synchronize
Prolonged QT
interval (on baseline EKG): Torsades de Pointes
Give
Magnesium
2 grams IV
May be repeated in 5-15 minutes
May be continued as infusion
Magnesium
3 to 20 mg/min IV for
Prolonged QT
c
Correct other
Electrolyte
abnormalities (
5H5T
)
Stop all medications that prolong
QT Interval
Do NOT give any AV Nodal blocking agents (e.g.
Amiodarone
,
Beta Blocker
s,
Calcium Channel Blocker
s)
Do NOT give any agent that prolongs QTc (e.g.
Procainamide
)
Reverse toxic ingestions and
Poisoning
s
Consider overdrive pacing to
Heart Rate
of 100 bpm
Consider
Isoproterenol
in refractory cases with
Bradycardia
(used historically, controversial)
Increases
Heart Rate
and shortens the
QT Interval
Normal
QT Interval
(on baseline EKG): Polymorphic Ventricular Tachycardia
Exercise
caution that QTc is normal (not Torsades de Pointes)
All agents described below can be lethal in Torsades de Pointes
If in doubt, treat as Torsades de Pointes (esp.
Magnesium
)
Myocardial Ischemia
(most common)
Beta Blocker
s
Emergent cardiac catheterization for revascularization
Consider
Amiodarone
150 mg IV (caution)
Catecholamine
rgic
Ventricular Tachycardia
Consider
Beta Blocker
s
Brugada Syndrome
Consider
Isoproterenol
Miscellaneous management of contributing factors
Hypoxia
management
Electrolyte
abnormality correction (e.g.
Potassium
,
Magnesium
)
References
Vandersteenhoven and Brady (2026) Crit Dec Emerg Med 40(2): 13-4
Type your search phrase here